Women's Health
Basic InformationLatest News
Postpartum Depression Rates Have Tripled for New Moms During PandemicNew Law Expands Care for Rape VictimsMammograms Can Also Highlight Heart Risks: StudyDrug Could Be Non-Antibiotic Alternative to Treat UTIsAntidepressants Often Ineffective for Depression in PregnancyMenopause May Mean More Sleep Apnea and  Painful JointsA Healthy Mouth Can Mean a Healthy Heart for Older WomenRacism in Youth Leaves Black Women With  Lasting Risk of DepressionCould Migraines Raise Odds for Complications in Pregnancy?Which New Moms Are at Highest Risk for Postpartum Depression?IUDs a Very Effective Form of Birth Control, Study ConfirmsOver Half of U.S. Abortions Now Done With PillsU.S. Deaths to New Mothers Rose During Pandemic, Minorities Hit HardestInsomnia Drug Might Also Ease Menopause Night SweatsEven Washing Dishes Helps an Older Woman's HeartSexual Harassment, Assault Tied to High Blood Pressure in WomenMany Challenges, But Pandemic Wasn't All Bad for New MomsSupplements for Menopausal Symptoms — Solutions or Snake Oil?AHA News: Damage From Preeclampsia May Be Seen Decades Later In the EyesWomen at Higher Odds for Side Effects From Some Cancer TreatmentsMajority of Pregnant U.S. Women Were Already in Poor Health: StudyWomen Should Take These 3 Things to HeartImmune-Based Therapy Shows Promise Against Advanced Breast CancersLoneliness Can Be Unhealthy Heartbreaker for Older WomenCould a Pap Test Help Detect Breast, Ovarian Cancers, Too?Kardashian's Figure a Tough Ideal for Women at Risk of Eating DisordersAny Change to Menstrual Cycle After COVID Vaccine Is Minor, Temporary: StudiesYoung Women at Higher Risk for Stroke Than Male Peers: StudyWeight Loss May Not Affect Fertility Treatment SuccessWhy Quitting Smoking Might Be a Bit Tougher for WomenCleaner Air Could Mean Healthier Brains for Older WomenImmune-Based Drug Fights Advanced Endometrial Cancer: StudyBreastfeeding May Protect a Mom's Heart Years LaterAHA News: Pregnant Women Living Under Negative Social Conditions May Face Higher Heart Disease RiskFour Factors in Midlife Predict a Healthy Old Age for WomenYou Can Help Prevent Cervical CancerCOVID Vaccine May Temporarily Add 1 Day to Menstrual Cycle: StudyCould New Blood Test Predict Pregnancy Complications?Unhealthy Heart May Be Bigger Threat to Women's Brains Than Men'sNew Clues to How Ovarian Cancer Begins -- and Might Be PreventedMore U.S. Women Are Retaining Their Hearing as They AgeWhy Are More Women Using Pot, Other Cannabis Products During Pregnancy?Chemicals in Hair, Beauty Products May Interfere With Hormones During PregnancyFDA Allows Abortion Pill to Stay Available by MailDrug Combo May Fight a Tough Form of Breast CancerStress May Be Stronger Trigger for Problem Drinking in Women Than MenRemoving Ovaries During Hysterectomy Before 50 Can Bring Health RisksGastro Symptoms of Menopause May Vary by RaceBlack Women Have Triple the Odds for Lymphedema After Breast Cancer SurgeryGene Test Spots Breast Cancer Patients Who Can Skip Post-Op Chemo
LinksSelf-Help Groups
Related Topics

Wellness and Personal Development
Mental Disorders

Gene Test Spots Breast Cancer Patients Who Can Skip Post-Op Chemo

HealthDay News
by By Robert Preidt and Ernie Mundell HealthDay Reporters
Updated: Dec 3rd 2021

new article illustration

FRIDAY, Dec. 3, 2021 (HealthDay News) -- A genetic test can identify older breast cancer patients who can forgo chemotherapy after surgery, even if the cancer has spread to nearby lymph nodes, a large international clinical trial shows.

"For decades, women with breast cancer that had spread to the axillary [armpit] lymph nodes were treated with chemotherapy after surgery, to reduce the risk of recurrence," explained Dr. Francisco Esteva, chief of breast medical oncology at Lenox Hill Hospital in New York City.

However, the findings suggest that post-op chemo might not be needed for all patients, so the study "represents a paradigm shift in medical oncology," said Esteva, who wasn't involved in the new research.

The study was led by Dr. Kevin Kalinsky, a SWOG investigator and a breast medical oncologist at the Winship Cancer Institute at Emory University in Atlanta. SWOG is a cancer clinical trials group funded by the U.S. National Cancer Institute. The findings were published Dec. 1 in the New England Journal of Medicine.

The study was conducted at 632 sites in nine countries and included more than 5,000 women with HR+, HER2- breast cancer that had spread to as many as three lymph nodes.

HR+ means that the breast tumor contains hormone receptors (HR) that make it sensitive to hormones such as estrogen. A majority of breast cancers are HR+. HER2 is short for "human epidermal growth factor receptor 2," which plays a role in how quickly breast cancer cells multiply. Tumors that are negative for HER2 are deemed less aggressive than HER2+ tumors.

According to the study authors, in about one-third of HR+, HER2- breast cancer patients cancer has already spread to their lymph nodes at the time of diagnosis. These women have a higher risk of cancer recurrence after treatment.

But do they all need chemotherapy? To help find out, the HR+/HER2- tumors of women enrolled in the study were tested for the expression of 21 genes in tumor tissue to assess their risk of a breast cancer recurrence. The test used is called the Oncotype DX multi-gene test.

All of the women had a gene recurrence score (RS) of 25 or lower on a 0-100 scale, indicating a low or intermediate risk of recurrence, Kalinsky's team found.

After surgery for their cancer, half of the women underwent chemotherapy followed by endocrine (hormonal) therapy, while the other half received endocrine therapy alone.

Five years after treatment, there were no clinically relevant or statistically significant differences between the two groups in either their rates of a recurrence of their breast cancer or any new invasive primary cancer.

However, there was a clear difference when they focused only on younger, premenopausal women, who accounted for about a third of the patients. In that group of women, those who received chemotherapy plus endocrine therapy had a 40% higher odds for a new primary cancer compared to those who received endocrine therapy alone.

In contrast, chemotherapy provided no additional benefits for postmenopausal women, according to the study.

In premenopausal patients, five-year cancer recurrence rates were 89% for women who received endocrine therapy alone vs. 93.9% for those who received chemotherapy and endocrine therapy. In postmenopausal patients, five-year recurrence rates were 91.9% percent vs. 91.3%, a difference that was not statistically significant, Kalinsky's group said.

“These are clinically meaningful and impactful data,” Kalinsky said in a SWOG news release.

The finding that postmenopausal women with some spread of cancer to their lymph nodes and a low gene-based risk score can skip post-surgical chemotherapy is good news, he added.

"This will save tens of thousands of women the time, expense and potentially harmful side effects that can be associated with chemotherapy," Kalinsky said.

On the other hand, premenopausal patients with lymph node involvement and low risk scores "likely benefit from chemotherapy," he said.

Esteva agreed.

"Based on the results from this study, a significant number of postmenopausal women with hormone receptor positive breast cancer and lymph node involvement [up to 3 positive lymph nodes] may be spared chemotherapy using the Oncotype DX multi-gene test," he said. "This is a major advance in our efforts to personalize breast cancer care using molecular assays to better define prognosis and predict potential benefit from specific therapies in individual patients."

Results from further analysis of the trial will also be presented at the 2021 San Antonio Breast Cancer Symposium on Dec. 8.

More information

The U.S. National Cancer Institute has more on breast cancer.

SOURCES: Francisco Esteva, MD, Chief, breast medical oncology, Lenox Hill Hospital, New York City; SWOG, news release, Dec. 1, 2021

328 W. Claiborne St.
P.O. Box 964
Alabama 36460
Tel: (251)575-4203

powered by centersite dot net